Deutsche Bank’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-40,215
| Closed | -$161K | – | 3664 |
|
|
2025
Q2 | $161K | Hold |
40,215
| – | – | ﹤0.01% | 3063 |
|
|
2025
Q1 | $36.6K | Hold |
40,215
| – | – | ﹤0.01% | 3425 |
|
|
2024
Q4 | $111K | Buy |
40,215
+9,055
| +29% | +$34.4K | ﹤0.01% | 3263 |
|
|
2024
Q3 | $163K | Buy |
31,160
+13,461
| +76% | +$69.9K | ﹤0.01% | 3018 |
|
|
2024
Q2 | $78.9K | Buy |
17,699
+2,284
| +15% | +$11.1K | ﹤0.01% | 3189 |
|
|
2024
Q1 | $118K | Sell |
15,415
-819
| -5% | -$4.49K | ﹤0.01% | 3093 |
|
|
2023
Q4 | $69.2K | Hold |
16,234
| – | – | ﹤0.01% | 3367 |
|
|
2023
Q3 | $68.2K | Buy |
+16,234
| New | +$82.6K | ﹤0.01% | 3329 |
|
|
2022
Q2 | – | Sell |
-7,810
| Closed | -$32K | – | 4221 |
|
|
2022
Q1 | $32K | Sell |
7,810
-918
| -11% | -$5.4K | ﹤0.01% | 3960 |
|
|
2021
Q4 | $60K | Buy |
8,728
+452
| +5% | +$3.9K | ﹤0.01% | 3903 |
|
|
2021
Q3 | $96K | Sell |
8,276
-266
| -3% | -$4.15K | ﹤0.01% | 3917 |
|
|
2021
Q2 | $146K | Buy |
8,542
+609
| +8% | +$10.6K | ﹤0.01% | 3962 |
|
|
2021
Q1 | $157K | Buy |
7,933
+1,787
| +29% | +$39.4K | ﹤0.01% | 3761 |
|
|
2020
Q4 | $127K | Buy |
6,146
+1,716
| +39% | +$40.9K | ﹤0.01% | 3717 |
|
|
2020
Q3 | $116K | Buy |
+4,430
| New | +$110K | ﹤0.01% | 3476 |
|
Deutsche Bank's INZY Position: Q3 2025 in Review
Deutsche Bank sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 40,215 shares — an estimated $161K sold.
Deutsche Bank first reported a position in INZY in Q3 2020 and held it in 15 quarters. The position peaked at $163K in Q3 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Deutsche Bank reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Deutsche Bank sold 40,215 Inozyme Pharma shares in Q3 2025, an estimated $161K.
- Deutsche Bank first reported a position in Inozyme Pharma in Q3 2020 and held it in 15 quarters.
- Deutsche Bank's Inozyme Pharma position peaked at $163K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Deutsche Bank's 13F filing for Q3 2025, filed 13 Nov 2025.